Migraine is a kind of headache caused by abnormalities in the nervous system. According to neurovascular theory, migraine is associated with increased expression of calcitonin-related peptide (CGRP) in the surrounding tissues of the skull. Compared with traditional small molecule chemicals, biological drugs have the advantages of high specificity and low toxicity. We did a review of monoclonal antibodies therapies of migraine, focusing on CGRP and its receptor. Four drugs are on the market or in the clinical phase ��, namely erenumab, glcanezumab, fremanezumab, and eptinezumab. Some clinical trial results were summarized and three drugs on the market were compared. This article also discussed the limitations of monoclonal antibody drugs targeting CGRP and their future was prospected.
XU X B, LIU L, ZHAO L P, et al. Advances in the study of the relationship between pathophysiological mechanisms of migraine and 5-HT7 receptors [J]. Chin J Pain Med (�й���ʹҽѧ��־), 2018, 24(4):274-280.
[2]
LIU D D, GUO J S. Correlation between calcitonin gene-related peptide and trigeminal vascular system in migraine[J]. Chin J Mod Appl Pharm(�й��ִ�Ӧ��ҩѧ), 2015, 32(3):381-385.
[3]
EDVINSSON L. Headache advances in 2017: a new horizon in migraine therapy[J]. Lancet Neurol, 2018, 17(1):5-6.
[4]
GEPPETTI P, ROSSI E, CHIARUGI A, et al. Antidromic vasodilatation and the migraine mechanism[J]. J Headache Pain, 2012, 13(2):103-111.
[5]
RADDANT A C, RUSSO A F. Calcitonin gene-related peptide in migraine:intersection of peripheral inflammation and central modulation[J]. Expert Rev Mol Med, 2011, 13(36):1-22.
[6]
EDVINSSON L, HAANES K A, WARFVINGE K, et al. CGRP as the target of new migraine therapies-successful translation from bench to clinic[J]. Nat Rev Neurol, 2018, 14(6):338-350.
[7]
BENEMEI S, CORTESE F, LABASTIDA-RAMIREZ A, et al. Triptans and CGRP blockade-impact on the cranial vasculature[J]. J Headache Pain, 2017, 18(1):103.
[8]
AIYAR N, DISA J, PULLEN M, et al. Receptor activity modifying proteins interaction with human and porcine calcitonin receptor-like receptor(CRLR) in Hek-293 cells[J]. Mol Cell Biochem, 2001, 224(1-2):123-133.
[9]
REUTER U. A review of monoclonal antibody therapies and other preventative treatments in migraine[J]. Headache, 2018, 581(SI):48-59.
[10]
PELLESI L, GUERZONI S, PINI L A. Spotlight on anti-CGRP monoclonal antibodies in migraine:the clinical evidence to date[J]. Clin Pharm Drug Dev, 2017, 6(6):534-547.
[11]
SHI L, LEHTO S G, ZHU D X, et al.Pharmacologic characterization of AMG 334, a potent and selective human monoclonal antibody against the calcitonin gene-related peptide receptor[J]. J Pharmacol Exp Ther, 2016, 356 (1):223-231.
[12]
DE HOON J, VAN HECKEN A, VANDERMEULEN C, et al.Phase I, randomized, double-blind, placebo-controlled, single-dose, and multiple-dose studies of erenumab in healthy subjects and patients with migraine[J]. Clin Pharmacol Ther, 2018, 103(5):815-825.
[13]
RAFFAELLI B, REUTER U. The biology of monoclonal antibodies: focus on calcitonin gene-related peptide for prophylactic migraine therapy[J]. Neurotherapeutics, 2018, 15(2):324-335.
[14]
DODICK D W, ASHINA M, BRANDES J L, et al. Arise:a phase 3 randomized trial of erenumab for episodic migraine[J]. Cephalalgia, 2018, 38(6):1026-1037.
[15]
GOADSBY P J, REUTER U, HALLSTROM Y, et al. A controlled trial of erenumab for episodic migraine[J]. N Engl J Med, 2017, 377(22):2123-2132.
[16]
REUTER U, GOADSBY P J, LANTERI-MINET M, et al. Efficacy and tolerability of erenumab in patients with episodic migraine in whom two-to-four previous preventive treatments were unsuccessful:a randomised, double-blind, placebo-controlled, phase3b study[J]. Lancet, 2018, 392(10161):2280-2287.
[17]
MONTEITH D, COLLINS E C, VANDERMEULEN C, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of the CGRP binding monoclonal antibody Ly2951742 (galcanezumab) in healthy volunteers[J]. Front Pharmacol, 2017, 8:740.doi:10.3389/fphar.2017.00740.
[18]
SKLJAREVSKI V, OAKES T M, ZHANG Q, et al. Effect of different doses of galcanezumab vs placebo for episodic migraine prevention: a randomized clinical trial[J]. Jama Neurol, 2018, 75(2):187-193.
[19]
AYER D W, SKLJAREVSKI V, FORD J H, et al. Measures of functioning in patients with episodic migraine: findings from a double-blind, randomized, placebo-controlled phase 2B trial with galcanezumab[J]. Headache, 2018, 58(8):1225-1235.
[20]
STAUFFER V L, DODICK D W, ZHANG Q, et al. Evaluation of galcanezumab for the prevention of episodic migraine:the evolve-1 randomized clinical trial[J]. Jama Neurol, 2018, 75(9):1080-1088.
[21]
SKLJAREVSKI V, MATHARU M, MILLEN B A, et al. Efficacy and safety of galcanezumab for the prevention of episodic migraine: results of the evolve-2 phase 3 randomized controlled clinical trial[J]. Cephalalgia, 2018, 38(8):1442-1454.
[22]
ZHANG Q, RUFF D, PEARLMAN E, et al. Efficacy of galcanezumab in patients who failed to respond to preventives previously: results from evolve-1, evolve-2 and regain studies[J]. Headache, 2018, 582(SI):165-166.
[23]
DETKE H C, WANG S, SKLJAREVSKI V, et al. A phase 3 placebo-controlled study of galcanezumab in patients with chronic migraine:results from the 3-month double-blind treatment phase of the regain study[J]. J Headache Pain, 2017, 57(8):1336-1337.
[24]
COHEN-BARAK O, WEISS S, RASAMOELISOLO M, et al. A phase 1 study to assess the pharmacokinetics, safety, and tolerability of fremanezumab doses (225 mg, 675 mg and 900 mg) in Japanese and Caucasian healthy subjects[J]. Cephalalgia, 2018, 38(13):1960-1971.
[25]
SILBERSTEIN S D, DODICK D W, BIGAL M E, et al. Fremanezumab for the preventive treatment of chronic migraine[J]. N Engl J Med, 2017, 377(22):2113-2122.
[26]
DODICK D W, SILBERSTEIN S D, BIGAL M E, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine:a randomized clinical trial[J]. JAMA, 2018, 319(19):1999-2008.
[27]
ANDERPLUYM J, DODICK D W, LIPTON R B, et al. Fremanezumab for preventive treatment of migraine:functional status on headache-free days[J]. Neurology, 2018, 91(12):e1152-e1165.
[28]
DODICK D, JANELIDZE M, SAPER J, et al. Eptinezumab results for the prevention of episodic migraine through 1 year in the phase 3 promise-1 (prevention of migraine via intravenous eptinezumab safety and efficacy-1) trial[J]. Cephalalgia, 2018, 38(suppl 1):89-90.
[29]
WINNER P K, GOADSBY P, NAGY A, et al. Eptinezumab reduced migraine activity and achieved high migraine responder rates over weeks 1-12:results from the phase 3 promise-2 trial in chronic migraine[J]. Headache, 2018, 582(SI):73-74.
[30]
REUTER U. A review of monoclonal antibody therapies and other preventative treatments in migraine[J]. Headache, 2018, 58(suppl 1):48-59.
[31]
LODER E W, ROBBINS M S. Monoclonal antibodies for migraine prevention progress, but not a panacea[J]. Jama-J Am Med Assoc, 2018, 319(19):1985-1987.
[32]
DODICK D W, SILBERSTEIN S D, BIGAL M E, et al. Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial[J]. JAMA, 2018, 319(19):1999-2008.
2019, Vol. 54 
